Aroa Biosurgery Ltd (ARX) AI Stock Analysis

• Market Cap: AU$200.38M
• Dividend Yield: N/A
• Average Volume (3M): 302.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: 16.93%
• EPS Growth: 76.47%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 345,476,200
• 10 Day Avg. Volume: 330,836
• 30 Day Avg. Volume: 302,123
• PEG Ratio: 0.65
• Price to Book (P/B): 1.73
• Price to Sales (P/S): 1.90
• P/FCF Ratio: -25.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$1.16
• Price Target Upside: 100.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): <0.01
• Revenue Forecast (FY): AU$98.95M

• Rating: 56 Neutral
• Price Target: AU$0.58 ▼(-0.52% Downside)
• Action: Reiterated Date: 02/04/26
• Date: Action: Reiterated 02/04/26

The score is driven primarily by improving but still mixed financial performance (strong growth and balance sheet strength offset by losses and negative free cash flow). Technical signals are neutral-to-weak, and valuation is pressured by negative earnings and no dividend support.

Positive Factors

Revenue Growth

Sustained top-line growth indicates expanding clinical adoption of ECM products and broader market penetration. Over 2-6 months this durable trend supports operating leverage, funds commercial expansion, and underpins pathway to break-even as fixed costs are absorbed by higher volumes.

Balance Sheet Strength

A high equity ratio and low leverage provide resilience against reimbursement cycles and procedural volume variability. This enduring financial stability reduces refinancing risk, allows strategic CAPEX or R&D investment, and supports multi-quarter commercial scaling without urgent debt service pressure.

Improving Operational Margins

A transition to positive EBITDA signals durable improvements in cost structure, manufacturing efficiency, or pricing power. If sustained, healthier operating margins provide internal funding for growth, reduce dependence on external capital, and increase the company's ability to invest in commercialization and product development.

Negative Factors

Persistent Net Losses

Continued net losses indicate the company has not yet converted revenue growth into sustainable profits. Over coming quarters this can compress retained earnings, limit reinvestment, and necessitate external financing, raising dilution risk and constraining long-term return generation.

Negative Free Cash Flow

Ongoing negative FCF shows operations do not yet fund required capex and working capital. Persisting over months can force dependence on equity or debt raises, slow capacity buildouts, or delay commercialization initiatives, weakening the company’s ability to self-fund strategic execution.

Negative Return on Equity

A negative ROE despite a strong equity base suggests capital is not producing returns. If margins and profitability do not improve, this inefficiency can persist, eroding investor confidence and making future equity raises more dilutive or difficult, limiting long-term capital flexibility.

Aroa Biosurgery Ltd Business Overview & Revenue Model

Company Description

Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.

How the Company Makes Money

Aroa Biosurgery makes money primarily by selling its ECM-based medical device products to healthcare providers via medical device distribution channels. Revenue is generated from product sales used in clinical settings (e.g., hospitals, outpatient surgery centers, and wound care clinics), where the products are purchased for use in procedures and wound treatment. The company’s earnings are driven by (1) recurring demand tied to procedure volumes and wound care utilization, (2) the breadth of indications and use-cases for its ECM products across wound and surgical repair markets, and (3) commercial relationships with channel partners/distributors that market and sell these products into target geographies. Specific pricing, margin structure, customer concentration, or named partner terms: null.

Aroa Biosurgery Ltd Financial Statement Overview

Summary

Strong revenue growth and a robust balance sheet with high equity/low leverage support stability, but persistent net losses and still-negative free cash flow weigh on overall financial quality despite improving EBITDA in 2025.

Income Statement

Aroa Biosurgery Ltd has demonstrated solid revenue growth, with a significant increase from 2024 to 2025. The gross profit margin is strong, indicating efficient cost management. However, persistent negative net income and EBIT margins reflect ongoing profitability challenges. The negative EBITDA margin in previous years is a concern, though it has turned positive in 2025, showing operational improvements.

Balance Sheet

The balance sheet is robust with a high equity ratio, suggesting financial stability and a low debt burden. The debt-to-equity ratio is favorable, highlighting prudent leverage management. However, the return on equity is negative due to net losses, indicating inefficiencies in generating shareholder returns.

Cash Flow

Cash flow management shows improvement with a reduced negative operating cash flow. However, free cash flow remains negative, indicating challenges in generating sufficient cash to cover capital expenditures. The free cash flow to net income ratio is not applicable due to negative net income, but overall trends suggest gradual improvement in cash flow management.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	82.36M	76.97M	63.36M	59.31M	36.88M	20.51M
Gross Profit	70.39M	65.99M	54.10M	50.06M	28.17M	14.25M
EBITDA	5.06M	2.65M	-6.78M	683.92K	-3.75M	-7.05M
Net Income	-1.66M	-3.47M	-9.75M	-370.68K	-7.79M	-17.63M
Balance Sheet
Total Assets	95.27M	98.94M	101.88M	109.07M	104.71M	73.12M
Cash, Cash Equivalents and Short-Term Investments	20.71M	20.13M	27.73M	43.00M	53.35M	33.93M
Total Debt	6.14M	5.83M	6.82M	6.65M	5.46M	14.90M
Total Liabilities	14.34M	14.35M	14.79M	13.69M	11.30M	19.43M
Stockholders Equity	80.93M	84.59M	87.08M	95.38M	93.40M	53.69M
Cash Flow
Free Cash Flow	4.60M	-5.69M	-10.00M	-10.66M	-15.39M	-6.05M
Operating Cash Flow	5.73M	-2.33M	-6.76M	-3.53M	-10.86M	-4.68M
Investing Cash Flow	-10.79M	273.54K	9.31M	6.79M	-32.41M	-19.74M
Financing Cash Flow	-1.83M	-1.34M	-948.41K	-471.78K	34.98M	34.06M

Aroa Biosurgery Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ARX, the sentiment is Negative. The current price of 0.58 is below the 20-day moving average (MA) of 0.61, below the 50-day MA of 0.67, and below the 200-day MA of 0.66, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 36.80 is Neutral, neither overbought nor oversold. The STOCH value of 45.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ARX.

Aroa Biosurgery Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COH	65 Neutral	AU$10.74B	26.40	17.76%	1.64%	4.32%	9.24%
PNV	62 Neutral	AU$618.30M	70,799.02	11.87%	―	23.31%	151.32%
ARX	56 Neutral	AU$200.38M	-47.06	-3.80%	―	16.93%	76.47%
4DX	53 Neutral	AU$2.51B	-3.16	-890.76%	―	55.91%	22.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CYC	44 Neutral	AU$90.60M	-6.27	-54.48%	―	34.20%	-23.90%
EMV	44 Neutral	AU$144.52M	-10.00	-70.29%	―	―	-257.32%

Aroa Biosurgery Ltd Corporate Events

Aroa Biosurgery to Release Small Tranche of Escrowed Director Shares

Aroa Biosurgery Limited has announced that 70,055 fully paid ordinary shares will be released from voluntary escrow on 31 March 2026, following a similar 70,055-share release on 31 March 2025. Together these tranches represent just 0.04% of the company’s issued share capital, indicating only a minor change to the overall free float.

The escrowed shares were originally issued on 22 August 2024 to non-executive director Darla Hutton after receiving shareholder approval at the 2024 Annual General Meeting. As the shares are already quoted on the ASX, the release primarily formalises their trading status and signals a modest increase in liquidity without materially diluting existing shareholders.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.16 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Seeks ASX Quotation for New Shares Issued Under Employee Incentive Scheme

Aroa Biosurgery Limited has applied for quotation on the ASX of 442,961 new fully paid ordinary shares issued on 29 January 2026 under an employee incentive scheme. The additional securities, to trade under the company’s existing ARX ticker, modestly increase the company’s free float and reflect the ongoing use of equity-based remuneration to retain and incentivise staff, with limited immediate impact on capital structure but signalling continued commitment to employee alignment with shareholder interests.

The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.75 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Issues Investor-Focused February 2026 Business Update

Aroa Biosurgery has issued a February 2026 business update presentation aimed at investors, outlining general company information and educational material on its regenerative wound care technologies. The document emphasises that it is not a prospectus or securities offering, warns that any performance discussion includes inherently uncertain forward‑looking statements, and reiterates that product availability varies by region and results may differ between patients, framing the update as informational rather than promotional or advisory for investment decisions.

The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.75 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Poised to Gain From US Reimbursement Shift as New Data Backs Myriad

Aroa Biosurgery says its Symphony wound-care product is well placed to benefit from new US Medicare rules that set a single outpatient reimbursement rate of US$127.14 per square centimetre for skin substitutes, a move the company expects will squeeze out higher-priced rivals and support Symphony’s uptake in hospital outpatient departments where it already has inpatient relationships. The company also highlighted new clinical data from its MASTRR registry showing that Myriad achieves rapid vascularised tissue coverage in complex trauma cases with low complication and application rates compared with competing bioscaffolds, reinforcing its potential to lower total care costs, and reaffirmed FY26 guidance with revenue expected near the top of its NZ$92–100 million range and normalised EBITDA of NZ$5–8 million, underpinned by strong sales momentum and a favourable US reimbursement backdrop.

The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.75 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Schedules Investor Webinar to Detail Symphony Reimbursement and Clinical Data

Aroa Biosurgery Limited will host an investor webinar on 3 February, led by CEO Brian Ward and CFO James Agnew, to discuss a pre-market business update, including progress on Symphony™ and developments in US Medicare reimbursement, as well as newly published clinical data from the ongoing MASTRR study. The event signals the company’s efforts to deepen investor engagement and provide greater transparency around key growth drivers and clinical validation, with potential implications for its reimbursement outlook, product adoption and positioning in the US soft-tissue regeneration market.

The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.75 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Study Backs Efficacy and Cost Edge of Myriad Trauma Scaffold

Aroa Biosurgery announced new interim data from its large, ongoing MASTRR registry showing that its Myriad Matrix and Myriad Morcells ovine-ECM bioscaffolds delivered effective and economical treatment of complex trauma and acute care surgery wounds. In 49 patients with 61 challenging, often contaminated defects treated across four US Level I trauma centres, wounds achieved full vascularised tissue coverage in a median of 22.5 days, typically after a single application and with no device-related complications, while cost comparisons against other bioscaffolds indicated Myriad is cheaper per centimetre with equivalent or superior key outcomes. Management and participating surgeons said the findings validate Myriad as a cost‑effective option that can lower total hospital care costs, reinforcing Aroa’s evidence base—now exceeding 116 peer‑reviewed studies—and highlighting a US trauma surgery market opportunity of roughly US$450 million that the company views as a strategic growth focus.

The most recent analyst rating on (AU:ARX) stock is a Hold with a A$0.75 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

Aroa Biosurgery Options Lapse Following Unmet Vesting Conditions

Aroa Biosurgery Limited, a medtech firm specialising in biosurgical and regenerative tissue products for surgical and wound care applications, is listed on the Australian Securities Exchange under the code ARX. The company has announced the cessation of 6,753 ARXAAK options, which lapsed on 19 October 2025 after conditions attached to the rights were not satisfied, resulting in a small reduction of potential dilutive securities on issue but no change to the existing ordinary share capital.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.